Saturday, July 11, 2026

Drug profile · INN

orphenadrine hydrochloride

orphenadrine hydrochloride (DISIPAL) is a norepinephrine transporter inhibitor. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — orphenadrine hydrochloride
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

orphenadrine hydrochloride (DISIPAL) is a norepinephrine transporter inhibitor. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN orphenadrine hydrochloride
Brand DISIPAL
Mechanism Norepinephrine transporter inhibitor
Target Glutamate [NMDA] receptor
Route ORAL
Formulation TABLET

Mechanism of action

Norepinephrine transporter inhibitor

Primary target: Glutamate [NMDA] receptor

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. amantadine hydrochloride Glutamate [NMDA] receptor antagonist
  2. felbamate Glutamate [NMDA] receptor antagonist
  3. memantine hydrochloride Nervous system (N06)
  4. esketamine hydrochloride Glutamate [NMDA] receptor negative allosteric modulator
  5. ketamine hydrochloride Glutamate [NMDA] receptor negative allosteric modulator
  6. orphenadrine citrate Norepinephrine transporter inhibitor

Frequently asked questions

What is orphenadrine hydrochloride?

orphenadrine hydrochloride (DISIPAL) is a norepinephrine transporter inhibitor. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for orphenadrine hydrochloride?

DISIPAL is a marketed brand name for orphenadrine hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of orphenadrine hydrochloride?

orphenadrine hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.